Background: Since December 2019,
Coronavirus disease 2019 MESHD (
COVID-19 MESHD) has emerged as an international pandemic.
COVID-19 MESHD patients with
myocardial injury MESHD might need special attention. However, understanding on this aspect remains unclear. This study aimed to illustrate clinical characteristics and the prognostic value of
myocardial injury MESHD to
COVID-19 MESHD patients. Methods: This retrospective, single-center study finally included 304 hospitalized
COVID-19 MESHD cases confirmed by real-time RT-PCR from January 11 to March 25, 2020.
Myocardial injury MESHD was determined by serum high-sensitivity troponin I (Hs-TnI). The primary endpoint was
COVID-19 MESHD associated mortality. Results: Of 304
COVID-19 MESHD patients (median age, 65 years; 52.6% males), 88 patients (27.3%) died (61 patients with
myocardial injury MESHD, 27 patients without
myocardial injury MESHD on admission).
COVID-19 MESHD patients with
myocardial injury MESHD had more comorbidities (
hypertension MESHD, chronic
obstructive pulmonary disease MESHD,
cardiovascular disease MESHD, and
cerebrovascular disease MESHD); lower lymphocyte counts, higher
C-reactive protein HGNC (
CRP HGNC, median, 84.9 vs 28.5 mg/L, p<0.001), procalcitonin levels (median, 0.29 vs 0.06 ng/ml, p<0.001), inflammatory and immune response markers; more frequent need for noninvasive ventilation, invasive mechanical ventilation; and was associated with higher mortality incidence (hazard ratio, HR=7.02, 95% confidence interval, CI, 4.45-11.08, p<0.001) than those without
myocardial injury MESHD.
Myocardial injury MESHD (HR=4.55, 95% CI, 2.49-8.31, p<0.001), senior age,
CRP HGNC levels, and novel
coronavirus pneumonia MESHD (
NCP PROTEIN) types on admission were independent predictors to mortality in
COVID-19 MESHD patients. Conclusions: COVID patients with
myocardial injury MESHD on admission is associated with more severe clinical presentation and biomarkers.
Myocardial injury MESHD and higher HsTNI are both strongest independent predictors to COVID related mortality after adjusting confounding factors. In addition, senior age,
CRP HGNC levels and
NCP PROTEIN types are also associated with mortality. Trial registration: Not applicable.